ArticleJapanese journal of ophthalmology2026
Safety profile of intravenous methylprednisolone therapy for thyroid eye disease: a multicenter retrospective study.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate the safety profile of intravenous methylprednisolone (IVMP) in patients with thyroid eye disease (TED) and identify factors associated with major adverse events (AEs), focusing on age. STUDY
designMulticenter retrospective study.
methodsWe reviewed 369 patients with active TED treated with IVMP. AEs occurring during or within 1 month of treatment were classified as mild, severe, or life-threatening. Logistic regression analyses identified factors associated with hyperglycemia, liver dysfunction, and severe/life-threatening AEs, with age-based comparisons (≥70 vs <70 years). For severe/life-threatening AEs, Firth's penalized logistic regression was additionally performed as a sensitivity analysis.
resultsAEs occurred in 240 patients (65.0%); 231 (62.6%) were mild, and 15 (4.1%) were severe or life-threatening. Hyperglycemia and liver dysfunction occurred in 10.6% and 7.9%, respectively. In exploratory multivariable analyses, older age, diabetes mellitus, and high cumulative dose (>6000 mg) were associated with hyperglycemia. For severe/life-threatening AEs, older age was the most consistent associated factor in exploratory analyses, and this finding was unchanged in a sensitivity analysis using Firth's penalized logistic regression. Patients aged ≥70 years had significantly higher risks of both hyperglycemia and severe/life-threatening AEs.
conclusionIVMP for active TED is frequently associated with mild AEs, whereas severe or life-threatening events are uncommon but clinically important. Older age was the most consistent factor associated with severe/life-threatening AEs in exploratory analyses, and hyperglycemia risk was higher in older patients, patients with diabetes mellitus, and patients receiving higher cumulative doses. These findings support careful risk assessment and monitoring, particularly in elderly patients.
Indexed as
Identifiers
42690508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.